Stock Events

Stock Events

Savara 

€4.61
53
+€0.03+0.61% Thursday 06:03

Statistics

Day High
4.61
Day Low
4.61
52W High
5.85
52W Low
2.98
Volume
0
Avg. Volume
8
Mkt Cap
947.99M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-0.14
-0.13
-0.12
-0.12
Expected EPS
-0.133331
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-103.07MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow YB4P.MU. It's not an investment recommendation.
Apple
9
AAPL
NVIDIA
9
NVDA
NIO
9
NIO
Tesla
8
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor because it develops and markets therapies for treating cystic fibrosis, a key area of focus for Savara.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences competes in the biopharmaceutical space, focusing on serious respiratory conditions, among other areas, which overlaps with Savara's interests.
Insmed
INSM
Mkt Cap25.89B
Insmed Incorporated specializes in rare lung diseases, directly competing with Savara's development of treatments for similar conditions.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.99B
Arrowhead Pharmaceuticals is involved in developing therapies for lung-related diseases, making it a direct competitor to Savara.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics, while primarily focused on genetic medicine for rare diseases, represents broader competition in the biotech sector for companies like Savara.
Protagonist Therapeutics
PTGX
Mkt Cap9.34B
Protagonist Therapeutics is engaged in developing peptide-based drugs, a method that could be applied to conditions similar to those Savara targets, making them competitors.

About

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Show more...
CEO
Matthew Pauls
Employees
70
Country
United States
ISIN
US8051111016
WKN
000A2DQ2B

Listings

STU
DE
YB4P.STU
MU
DE
YB4P.MU
XNAS
US
SVRA
F
DE
YB4P.F

0 Comments

Share your thoughts

FAQ

What is Savara stock price today?▼
The current price of YB4P.MU is €4.61 EUR — it has increased by +0.61% in the past 24 hours. Watch Savara stock price performance more closely on the chart.
What is Savara stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Savara stocks are traded under the ticker YB4P.MU.
Is Savara stock price growing?▼
YB4P.MU stock has fallen by -3.23% compared to the previous week, the month change is a -2.66% fall, over the last year Savara has showed a +60.21% increase.
What is Savara market cap?▼
Today Savara has the market capitalization of 947.99M
When is the next Savara earnings date?▼
Savara is going to release the next earnings report on November 05, 2026.
What were Savara earnings last quarter?▼
YB4P.MU earnings for the last quarter are -0.14 EUR per share, whereas the estimation was -0.12 EUR resulting in a -13.27% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Savara revenue for the last year?▼
Savara revenue for the last year amounts to 0 EUR.
What is Savara net income for the last year?▼
YB4P.MU net income for the last year is -103.07M EUR.
How many employees does Savara have?▼
As of September 04, 2026, the company has 70 employees.
In which sector is Savara located?▼
Savara operates in the Health & Wellness sector.
When did Savara complete a stock split?▼
Savara has not had any recent stock splits.
Where is Savara headquartered?▼
Savara is headquartered in AUSTIN, United States.